spring
bank
announces
poster
presentation
society
immunotherapy
cancer
sitc
annual
meeting
hopkinton
globe
newswire
spring
bank
pharmaceuticals
nasdaq
sbph
biopharmaceutical
company
developing
novel
therapeutics
oncology
inflammatory
diseases
today
announced
upcoming
poster
presentation
sb
annual
meeting
society
immunotherapy
cancer
sitc
held
virtually
november
sb
spring
bank
intravenously
iv
sting
agonist
product
candidate
currently
evaluated
phase
clinical
trial
monotherapy
combination
roche
checkpoint
inhibitor
poster
presentation
include
update
progress
iv
sb
phase
trial
details
follows
title
phase
study
intravenously
administered
sb
alone
combination
atezolizumab
patients
advanced
solid
tumors
authors
jason
luke
md
et
poster
abstract
number
abstracts
posters
accessed
sitc
website
wednesday
november
edt
poster
also
made
available
publications
page
spring
bank
website
spring
bank
pharmaceuticals
spring
bank
pharmaceuticals
biopharmaceutical
company
engaged
discovery
development
novel
class
therapeutics
using
proprietary
small
molecule
nucleotide
platform
company
designs
compounds
selectively
target
modulate
activity
specific
proteins
implicated
various
disease
states
company
developing
sting
product
portfolio
lead
clinical
product
candidate
sb
immunotherapeutic
agent
treatment
selected
cancers
sting
antagonist
compounds
treatment
broad
range
inflammatory
diseases
sting
agonist
adc
program
potential
oncology
applications
spring
bank
media
mcneil
gray
rice
kristin
nugent
senior
account
supervisor
